SUPERNUS PHARMACEUTICALS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SUPERNUS PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $4.04M, a 24.92% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $9.12M.
- SUPERNUS PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $22.93M, a 645.69% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $3.23M, a 94.81% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2025 was $33.39M, a 173.81% increase from fiscal 2024.
- SUPERNUS PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2024 was $12.19M, a 163.92% increase from fiscal 2023.
- SUPERNUS PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2023 was $4.62M, a 62.81% decline from fiscal 2022.
- SUPERNUS PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2022 was $12.42M, a 75.10% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $4.04M 10-Q · filed 2026-08-03 | |
| 2026-03-31 | $9.12M 10-Q · filed 2026-08-03 | |
| 2025-12-31 | $33.39M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $22.93M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $3.23M 10-Q · filed 2026-08-03 | |
| 2025-03-31 | -$1.30M 10-Q · filed 2026-08-03 | |
| 2024-12-31 | $12.19M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $3.08M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $1.66M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $1.57M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $4.62M 10-K · filed 2026-03-02 | |
| 2023-09-30 | -$230.00K 10-Q · filed 2024-11-04 | |
| 2023-06-30 | $1.95M 10-Q · filed 2024-11-04 | |
| 2023-03-31 | $1.81M 10-Q · filed 2024-11-04 | |
| 2022-12-31 | $12.42M 10-K · filed 2025-02-25 | |
| 2022-09-30 | $6.46M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $2.27M 10-Q · filed 2023-11-08 | |
| 2022-03-31 | $866.00K 10-Q · filed 2023-11-08 | |
| 2021-12-31 | $7.09M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $524.00K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $2.75M 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $2.25M 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $4.36M 10-K · filed 2023-03-09 | |
| 2020-09-30 | $77.00K 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $1.44M 10-Q · filed 2021-11-05 | |
| 2020-03-31 | $32.00K 10-Q · filed 2021-11-05 | |
| 2019-12-31 | $3.93M 10-K · filed 2022-04-13 | |
| 2018-12-31 | $11.58M 10-K · filed 2021-03-08 | |
| 2012-12-31 | $92.38M 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |